Search
Secnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigationalIt is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class … [A27210] Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
Fondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalOnce bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Enflurane
go.drugbank.com/drugs/DB00228ApprovedVet approvedWithdrawnEnflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.
Potassium alum
go.drugbank.com/drugs/DB09087ApprovedWithdrawnPotassium alum is considered by the FDA as a generally recognized as safe (GRAS) substance. … Potassium alum is formed by large, transparent crystals that are used in different products like food or drugs as a buffer, neutralizing or forming agent.[T60]
Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigationalIt was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. … [A192789] Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Iopromide
go.drugbank.com/drugs/DB09156Approved[A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs
Insulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigationalInsulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … [A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETProducts: TRESIBA® 100 U/ML, Tresiba® FlexTouch® 100 U/ml Solution for Injection